Compare CDRO & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDRO | RGNX |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | Luxembourg | United States |
| Employees | 325 | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 363.1M | 418.1M |
| IPO Year | N/A | 2015 |
| Metric | CDRO | RGNX |
|---|---|---|
| Price | $8.98 | $8.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $9.00 | ★ $28.75 |
| AVG Volume (30 Days) | 12.0K | ★ 501.7K |
| Earning Date | 02-28-2023 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | $11.31 | $51.21 |
| Revenue Next Year | $6.75 | $19.08 |
| P/E Ratio | $305.95 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $5.18 | $6.89 |
| 52 Week High | $9.68 | $16.19 |
| Indicator | CDRO | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 65.64 | 46.91 |
| Support Level | $7.48 | $8.68 |
| Resistance Level | $9.68 | $9.29 |
| Average True Range (ATR) | 0.34 | 0.48 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 46.40 | 28.57 |
Codere Online Luxembourg SA is an international online casino gaming and online sports betting group focused on providing its customers with a safe and enjoyable online gaming experience. It currently operates in Spain, Mexico, Colombia, and Other countries. where it offers its users the ability to play online casino games and bet on sports events. Online casino offerings include the full portfolio of games typically available in land-based casinos, gaming halls and gambling establishments, such as slot machines, table games, and bingo. Online sports betting involves a user placing a wager on an event at some fixed odds determined by Codere Online. The company derives maximum revenue from Mexico.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.